News

Biopharma going public
Enlarge image

Stock marketNetherlandsUKBelgium

Biopharma going public

10.07.2014 - Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

Abzena Ltd. announced its intention to launch an initial public offering and placing on June 16th. The London-based company, recently formed by combining its two subsidiaries Polytherics and Antitope, applied for the admission of its shares to trading on the AIM market of the London Stock Exchange under the symbol "ABZA". Now, the drugmaker has placed 25 million new ordinary shares at a placing price of €1 per share. In addition, almost 3.4 million existing ordinary shares are being sold at the placing price. John Burt, CEO of Abzena said: "Our forthcoming admission to AIM mark important milestones in Abzena’s development and provides a platform for us to grow our existing business and expand our offering."

Abzena is scheduled to start trading on July 10th – just like antibody specialist Argen-x. The Dutch company will be listed on Euronext Brussels and under the symbol “ARGX". The offering was priced at €8.50 for each of the 4.7 million new shares issued. In addition, there is an over-allotment option to subscribe to additional new shares worth €4m, which would bring the total amount of the capital increase up to €44m.  Tim Van Hauwermeiren, CEO of Argen-x  said: "The funds that we have raised through our successful IPO from investors in Europe and the US will enable Argen-x to advance the clinical development of our differentiated therapeutic antibody candidates." Argen-x' partner Shire purchased shares for a total of €12m, which represents 9.1% of the capital of Argen-x, and other existing investors purchased shares for a total of around €7.2m.

© european-biotechnology-news.com/um

M&AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M&ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

M&AFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

BioeconomyBelgiumUK

30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.

ConventionEUUK

25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.

InvestmentGermanyNetherlands

24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.

InvestmentNetherlands

20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/4.html

Events

All Events

Partner-Events

Vilnius (LT)

Life Sciences Baltics

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ADDEX (CH)4.29 CHF18.51%
  • COSMO PHARMACEUTICALS (CH)179.10 CHF7.76%
  • NEUROVIVE PHARMACEUTICAL AB (S)55.75 SEK6.19%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • BAVARIAN NORDIC (D)15.82 EUR-8.02%

TOP

  • SANTHERA (CH)72.80 CHF137.5%
  • CELLECTIS (F)13.63 EUR103.4%
  • ADDEX (CH)4.29 CHF92.4%

FLOP

  • THROMBOGENICS (B)8.92 EUR-50.4%
  • MERCK KGAA (D)64.16 EUR-50.1%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)72.80 CHF3576.8%
  • GW PHARMACEUTICALS (UK)444.50 GBP828.4%
  • IXICO (UK)55.50 GBP320.5%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.3%
  • CYTOS (CH)0.25 CHF-92.8%
  • THROMBOGENICS (B)8.92 EUR-72.4%

No liability assumed, Date: 09.07.2014